about
Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunctionThe cognitive outcome of hemispherectomy in 71 childrenAuditory confrontation naming in Alzheimer's diseaseInhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.Longitudinal medication usage in Alzheimer disease patients.Clinical features associated with costs in early AD: baseline data from the Predictors Study.Seizures in Alzheimer disease: who, when, and how common?Neuropsychological and neuroradiological correlates in Huntington's disease.Change in body mass index before and after Alzheimer's disease onset.Patterns of word-list generation in mild cognitive impairment and Alzheimer's diseaseEpisodic memory in dementia: Characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseasesCognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.Health-care use and cost in dementia caregivers: Longitudinal results from the Predictors Caregiver Study.A recommended scale for cognitive screening in clinical trials of Parkinson's disease.Everyday functioning in mild cognitive impairment and its relationship with executive cognition.Delusions and hallucinations are associated with worse outcome in Alzheimer diseaseMotor signs predict poor outcomes in Alzheimer disease.Functional ("psychogenic") amnesia.Gray matter in amnestic mild cognitive impairment: voxel-based morphometry.Disruptive behavior as a predictor in Alzheimer diseaseInternet-based screening for dementia risk.Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought.Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function.The fate of the 0.5s: predictors of 2-year outcome in mild cognitive impairment.The physical environment influences neuropsychiatric symptoms and other outcomes in assisted living residents.Extended results of the Alzheimer's disease anti-inflammatory prevention trial.Cognitive predictors of everyday functioning in older adults: results from the ACTIVE Cognitive Intervention Trial.Differential impairment of spatial location memory in Huntington's disease.Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the communityBetting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's diseaseMeasurement equivalence in ADL and IADL difficulty across international surveys of aging: findings from the HRS, SHARE, and ELSA.The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland.Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.Incidence and predictors of seizures in patients with Alzheimer's disease.Predictors of caregiver unawareness and nontreatment of dementia among residents of assisted living facilities: the Maryland Assisted Living Study.Depression in assisted living is common and related to physical burden.Parallel but not equivalent: challenges and solutions for repeated assessment of cognition over time.Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's diseaseHarmonizing Measures of Cognitive Performance Across International Surveys of Aging Using Item Response Theory.Comparison of costs of care between patients with Alzheimer's disease and dementia with Lewy bodies.
P50
Q26866192-45ED0F15-7D3E-44DA-9F4D-8F0E0A693806Q28249231-896DF7D6-6593-44B4-AC56-EDA3643B56E7Q30473248-FD5C9E2D-83D9-4C5B-90A6-13562FD34B92Q30530185-371E58AD-BAB1-4478-98DB-768FF51195D1Q30549920-A760FE1D-F73C-4B91-A84C-8AC9DF64B488Q31036417-F4C8847F-59CC-4741-8C4E-BF0BA69A6515Q33157686-990FBC48-BDA5-4BC5-8045-1A866965F32FQ33630738-FBA2A19E-8705-47F9-A854-7B78F19C3E78Q33632560-EF40CB91-0C2C-47B4-A940-72FD09C3BF64Q33802813-F560786C-922F-4168-9B04-853CC7E481CEQ33997691-EE0FE5A0-5726-41F1-B91A-D724FC44A41EQ34077849-8209C3A7-602C-44EF-9FF2-A627EA4F0864Q34183841-83FC044D-6103-4FE0-A65C-0581A6F9002FQ34300160-F0F3EAD6-5608-4E5A-93E4-DB9005338429Q34330419-7FC3908B-B81B-4A77-A827-D64C4906DD09Q34528084-09E7F863-128A-4624-9B0A-702F2461B08AQ34529965-481D3A95-6B01-4DC2-A07A-DC85E3E2D958Q34568572-B900229E-A9FD-4D94-96DA-D8269D97CD7EQ34584849-D547AE14-3D69-47B7-8AA5-7222D17D226AQ34585956-B7A0831E-50A8-4B14-85DC-898D053416C7Q34600572-975A8262-D650-407C-8E4B-43411E9A834FQ34611603-61C6AF90-0FB3-49FA-B00D-5C395EAAF605Q34668064-5BAE4F64-FAB0-4AAD-8509-458BDE794FF8Q34807653-10B983BE-1626-49B3-AF91-78F5F5F60E7AQ35127820-CFC0EC74-9B77-481B-A324-57C3235FCB7EQ35146385-23E39006-3E21-489B-B103-B997BDF5FAFFQ35161253-1CB0853C-614D-42C8-A2CC-A2BA41645FB1Q35484926-EF4A7473-80FC-4531-9B4F-B49C1989DB7CQ35588248-67BE2749-2F3A-4823-97BB-65EBE2F8169AQ35696129-C1D0D5F7-9A9B-4EAD-ABCD-D5A7910402F4Q35700539-0B0A4D05-AB2C-4199-A9B1-7B18AFF23017Q35902448-D4FFAA2B-3BAB-4637-A04A-6F2835190150Q36059092-D3C63300-404E-45F2-AF2D-46AFDF6ABE2CQ36474116-804C3BD8-6C06-439F-84F1-10CE4D4EC67EQ36544211-01C80F65-71B0-4154-A8AB-1E7D10AC46E5Q36603778-07555615-14E0-4666-8569-1CBCCA630AA0Q36616748-7BF6194C-A87E-4F09-83F3-2897D9C6F347Q36788139-D30BC33E-57DA-420D-9A0D-F0C815F3969DQ36807315-641D81B0-0BB5-4E3A-97E5-4E87D35DFC27Q36808790-2344AFA1-E4DB-4EB5-B9AB-B0AF1008119C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jason Brandt
@ast
Jason Brandt
@en
Jason Brandt
@es
Jason Brandt
@nl
Jason Brandt
@sl
type
label
Jason Brandt
@ast
Jason Brandt
@en
Jason Brandt
@es
Jason Brandt
@nl
Jason Brandt
@sl
prefLabel
Jason Brandt
@ast
Jason Brandt
@en
Jason Brandt
@es
Jason Brandt
@nl
Jason Brandt
@sl
P106
P1153
7201483947
P21
P31
P496
0000-0001-7381-6244